210 related articles for article (PubMed ID: 19638464)
1. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
Johnson EE; Yamane BH; Buhtoiarov IN; Lum HD; Rakhmilevich AL; Mahvi DM; Gillies SD; Sondel PM
Clin Cancer Res; 2009 Aug; 15(15):4875-84. PubMed ID: 19638464
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.
Connor JP; Cristea MC; Lewis NL; Lewis LD; Komarnitsky PB; Mattiacci MR; Felder M; Stewart S; Harter J; Henslee-Downey J; Kramer D; Neugebauer R; Stupp R
BMC Cancer; 2013 Jan; 13():20. PubMed ID: 23320927
[TBL] [Abstract][Full Text] [Related]
6. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
8. Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer.
Ito F; Ku AW; Bucsek MJ; Muhitch JB; Vardam-Kaur T; Kim M; Fisher DT; Camoriano M; Khoury T; Skitzki JJ; Gollnick SO; Evans SS
PLoS One; 2015; 10(11):e0143370. PubMed ID: 26599402
[TBL] [Abstract][Full Text] [Related]
9. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
[TBL] [Abstract][Full Text] [Related]
10. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.
Ko YJ; Bubley GJ; Weber R; Redfern C; Gold DP; Finke L; Kovar A; Dahl T; Gillies SD
J Immunother; 2004; 27(3):232-9. PubMed ID: 15076141
[TBL] [Abstract][Full Text] [Related]
12. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
[TBL] [Abstract][Full Text] [Related]
13. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.
Morris ZS; Guy EI; Francis DM; Gressett MM; Werner LR; Carmichael LL; Yang RK; Armstrong EA; Huang S; Navid F; Gillies SD; Korman A; Hank JA; Rakhmilevich AL; Harari PM; Sondel PM
Cancer Res; 2016 Jul; 76(13):3929-41. PubMed ID: 27197149
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
Gameiro SR; Higgins JP; Dreher MR; Woods DL; Reddy G; Wood BJ; Guha C; Hodge JW
PLoS One; 2013; 8(7):e70417. PubMed ID: 23894654
[TBL] [Abstract][Full Text] [Related]
15. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation.
Nakagawa H; Mizukoshi E; Iida N; Terashima T; Kitahara M; Marukawa Y; Kitamura K; Nakamoto Y; Hiroishi K; Imawari M; Kaneko S
Cancer Immunol Immunother; 2014 Apr; 63(4):347-56. PubMed ID: 24384836
[TBL] [Abstract][Full Text] [Related]
16. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
17. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
Schwager K; Hemmerle T; Aebischer D; Neri D
J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.
Tanaka N; Sivanandham M; Wallack MK
J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):283-93. PubMed ID: 7881637
[TBL] [Abstract][Full Text] [Related]
19. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.
van den Heuvel MM; Verheij M; Boshuizen R; Belderbos J; Dingemans AM; De Ruysscher D; Laurent J; Tighe R; Haanen J; Quaratino S
J Transl Med; 2015 Jan; 13():32. PubMed ID: 25622640
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
